- Global Pharma News & Resources

STipe Therapeutics appoints Dr Sonia Quaratino to chair the Scientific and Clinical Advisory Board

Aarhus, Denmark, and Copenhagen, Denmark, 15 May 2020, STipe Therapeutics (STipe), a company with a novel approach to leverage the stimulator of interferon genes (STING) Pathway, a major driver of innate immunity, by a unique sensitization mechanism, announced the appointment of seasoned industry expert, Dr Sonia Quaratino as chair of the Scientific and Clinical Advisory Board.


“We are excited to welcome Sonia Quaratino to chair our expanding Scientific and Clinical Advisory Board. STipe will tremendously benefit from her clinical development and immunology research expertise, as well as her in depth knowledge of immunomodulators” said Dr Claus Elsborg Olesen Chief Executive Officer of STipe. “We look forward to drawing on her extensive experience to support our novel immunomodulatory cancer therapies and she will play a vital role in the expansion of the Advisory Board as STipe progresses towards the clinic.”


Dr Quaratino has over 20 years' experience in clinical development and immunology research.  She currently serves as Chief Medical Officer at Kymab, a clinical-stage biopharmaceutical company developing monoclonal and bispecific antibody-based therapeutics. Prior to that she was Global Clinical Program Leader - Translational Clinical Oncology  at Novartis, responsible for the clinical development of proprietary therapeutic antibody programmes in immuno-oncology. Previously, Dr Quaratino was Senior Medical Director and Immunology Advisor at Merck Serono, where she was responsible for the clinical development of various immunomodulators. She holds a Medical Degree and a Doctorate in Hematology-Oncology from the University of Palermo, Italy and a PhD in Immunology from Imperial College London, UK. For a number of years she was a Professor of Immunology at the University of Southampton where she focused on the pathogenic mechanisms underlying chronic inflammatory diseases and the interface between autoimmunity and cancer.


“The STipe Therapeutics technology truly represents a novel approach to modulate the STING pathway, and I am delighted to work more closely with the Company advancing their technology. I am looking forward to supporting STipe Therapeutics by assembling a dynamic and competent Advisory Board to aid the advancement of the Company’s treatments for a broad range of cancers” said Dr Sonia Quaratino, Scientific and Clinical Advisory Board Chair.

Editor Details

  • Company:
    • STipe Therapeutics (STipe),
  • Name:
    • STipe Therapeutics (STipe),
Last Updated: 20-May-2020